ABVX:EPA
Abivax SA
€ ८१.८५
arrow_downward
-०.७९%(-०.६५) 1D
नोभेम्बर १३, १४:२६:४४ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€ ८१.२५
High
€ ८२.२५
Low
€ ८०.८०
Mkt. cap
७.१७ अरब
Avg. vol.
१.१० लाख
Volume
११.४७ हजार
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
Open
€ ८१.२५
High
€ ८२.२५
Low
€ ८०.८०
Mkt. cap
७.१७ अरब
Avg. vol.
१.१० लाख
Volume
११.४७ हजार
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
News stories
From web sources and news partners
Idéal Investisseur
·
१ दिन पहिले
Abivax stock down 26% over the quarter despite its rebound
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees९८
Founded२०१३ डिसेम्बर ४
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com